Skip to main content
Premium Trial:

Request an Annual Quote

Epigenetics Sequencing Firm Cambridge Epigenetix Raises $5.5M

NEW YORK (GenomeWeb) – Epigenetics sequencing firm Cambridge Epigenetix today announced the completion of a Series A financing round that raised $5.5 million.

The company also announced the appointment of Fedja Bobanovic as its CEO.

New Science Ventures led the financing, and founding investors Syncona Partners and Cambridge Enterprise participated in the round. Bobanovic said that the funds will be used to continue exploring commercial applications for the firm's products, as well as for R&D.

The UK firm was founded in 2012 as a spinout from Shankar Balasubramanian's laboratory at the University of Cambridge and leverages an epigenetic sequencing technique called oxidative bisulfite sequencing, or ox-BS sequencing, a method for the quantitative, single-base resolution sequencing of 5-hydroxymethylcytosine and 5-methycytosine. In 2013, Cambridge Epigenetix launched the TrueMethyl kit.

Also, Bobanovic has joined the company from Danaher where he was a vice president and general manager for the Europe, Middle East, and Africa region at AB Sciex. Somu Subramanian, a founding partner at New Science Ventures, has also joined Cambridge Epigenetix's board.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.